KR100576129B1 - Composition comprising Notoginseng Radix extract for promoting release of growth hormone - Google Patents

Abstract

The present invention relates to a composition for promoting growth hormone secretion as an active ingredient Samchil-geun extract.

Samchil-geun extract of the present invention acts on the pituitary cells to promote the secretion of growth hormone, and because it strongly increases the growth hormone in vitro ( in vitro ) as well as in vivo , microcertification, dwarfism, development of children It can be usefully used for the prevention and treatment of growth diseases such as sluggishness and growth slowdown.

Description

Composition comprising Notoginseng Radix extract for promoting release of growth hormone             

1 is a graph showing the growth hormone measured at regular time intervals from the tail vein after administration of the three-stage muscle extract of the present invention to the jugular vein of the rat.

The present invention relates to a composition for promoting growth hormone secretion as an active ingredient Samchil-geun extract.

Growth hormone (GH) is a protein secreted by the pituitary gland of animals and is a peptide hormone consisting of 191 amino acids. These growth hormones have been isolated from animals for a long time and have been used mainly for the treatment of dwarfism patients. They have various effects because they inhibit protein loss and delay physiological aging in older adults or the elderly. It can be used to treat diseases (Horber, FF and Haymond, MW, J. Clin. Invest ., 1990, 86, 265-272).

Continuous administration of growth hormone increases body weight, muscle, and fat weight to prevent aging-related diseases. Even when administered temporarily, plasma insulin and IGF-1 (Insulin-like growth factor-1) It is known to increase the concentration and decrease the protein concentration in the urine (Kohrt, WM et al., Med. Sci. Sports Exerc ., 1992, 24, 832-837; Zachweija, JJ et al., Am. J. Physiol , 1994, 266 (Endocrinol. Metab. 29), E840-844). In addition, it has been reported to increase the weight and size of the liver and improve the synthesis of proteins in terminal tissues such as muscle, bone and connective tissue (Kaiser, FE et al., J. Am. Geriatr. Soc ., 1991, 39, 235-240; Marcus, R. et al., J. Clin. Endocrino. Metab ., 1990, 70, 519-527).

Until now, the effects of simultaneous growth hormone releasing hormone (GHRH) and arginine on children and adults with congenital hypopituitarism have been shown to be effective. Growth hormone response was higher in children than in adults, and growth hormone deficiency was higher in patients with growth hormone deficiency than in many types of pituitary hormone deficiency, and patients with residual vascular components of the pituitary gland Obtained higher results. Responsiveness of growth hormone to GHRH and arginine tends to decrease with age ( J. Clin. Endocrinol. Metab ., 2001, 86 (4), 1574-79), and endogenous growth hormone secretagogues. It was effective when the ligand, ghrelin, was administered to growth hormone deficient mice ( Diabetes , 2001, 50 (2), 227-32), MK-677, an active growth hormone secretagogue, and aren, a potent inhibitor of bone resorption. The administration of alrondron (alendronate) increases bone mineral density in postmenopausal women with postmenopausal osteoporosis because it maintains a relatively higher rate of formation than when arendronate is administered alone. The effect of MK-677 and arendronate on IGF-1 levels was increased in both MK-677 alone or in combination with arendronate and increased IGF-1 levels and alleviated decreased bone formation. The bone mineral density of the neck increased while the bone mineral density of the lumbar spine and hip did not increase. The metabolic effect of growth hormone through MK-677 reduced the direct inhibitory effect of arendronate on bone formation ( J. Clin. Endocrinol. Metab ., 2001, 86 (3), 1116-25).

In the past, growth hormone was mainly extracted from the cadaveric pituitary gland, but in the process it was found to cause the disease Creutzfeldt-Jakob disease in patients receiving growth hormone. As such, there is a risk that other diseases may be introduced into the patient during the separation process, and growth hormone isolated from the carcass has been limited in its use. With the development of genetic engineering, recombinant growth hormone produced using microorganisms can be produced and supplied in large quantities, and the risk of infection of other diseases is low, so the protein preparation including recombinant growth hormone occupies most of the market for dwarfism. The method of administering the recombinant recombinant growth hormone into the body is made by intramuscular injection using a syringe because the growth hormone itself is a huge protein and cannot be orally administered. As such, although recombinant growth hormone can be produced in large quantities, in recent years, attempts to develop oral formulations have been actively conducted due to the high cost required for a certain treatment period and the inability to use injection due to the impossibility of oral administration. It's going on.

The basic requirement for growth hormone preparations for oral administration is to have high absorption rate in the body and to have biological activity that can selectively stimulate growth hormone secretion. In order to have a high absorption rate in the body by oral administration, the smaller the molecular weight is advantageous, and to perform the physiological activity in the body smoothly, it must have a special physical and chemical properties.

Representatives that have been studied as substances with these basic requirements and have been developed up to the clinical trial stage include organically synthesized L-692, 429 ( Horm. Res. , 1993, 40, 109-115) and L-163, 191 ( PNAS). , 1995, 92, 7001-7005), and the peptide compounds GHRP-2 ( Endocrinology , 1994, 140, R9-R13), GHRP-1 ( J. Neuroendocrinology , 1994, 6, 185) and hexarelin (Hexarelin: His -D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2). The materials are newly researched and developed using the basic structure of GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), a peptide compound commonly known in the early 1980s.

Recently, the approach of developing a new material has been in the spotlight by using a chemical library to search a large amount of candidates. In addition, it is possible to find a peptide library composed of short peptides and a natural environment. A natural library of materials present is also being used to develop these new materials. Developing new drugs using such a wide variety of libraries is considerably more efficient than traditional approaches in terms of the time and cost of development, so developed pharmaceutical companies have long been active in developing new drugs using their libraries. come. Specifically, L-163, 191, and hexarelin may be referred to as substances developed by this approach.

Originally it varies from animal to animal, but in humans there is 44 amino acids of GHRH. The regulation of growth hormone secretion in the human body is a hormone called GHRH which promotes the secretion of growth hormone and somatostatin, which inhibits the growth hormone secretion. It has been known to act to secrete.

GHRP-6 is a useful synthetic peptide that is less effective than the GHRH in biological activity but is highly compressed in terms of molecular weight size (Journal of Endocrinology, 1995, 10 (1), 1-9). Since the development of GHRP-6, many researchers have reported that GHRP-6 does not act on the same receptors as GHRH, and the possibility of the presence of new receptors via these synthetic growth hormone secretagogues. Has been raised ( Endocrinology , 1989, 124, 2791). This possibility has been proven by Merck researchers to reveal the cDNA sequence of the growth hormone secretagogue receptor in the pituitary archromediate and hypothalamus of pigs and humans. ( Science , 1996, 273, 974-977). This fact proved the synergism between the previously found growth hormone secretagogue and the synthetic compound growth hormone secretagogue, and is more interested in the identification of substances that exist in the body and are expected to play the same role as GHRH. This situation is increasing.

L-692, 429 ( Science , 1993, 260, 1640-1643), developed by Merck, USA, has been shown to selectively secrete growth hormone, and has been shown to have an effective body absorption rate even in animal testing. However, the results of human experiments, unlike that of the animal had a problem that the absorption is not very high upon oral administration. Therefore, L-163, 191 was developed to improve this problem, which is the compound that increased oral absorption rate, which is the biggest problem of the growth hormone secretagogues, which has been developed previously, is reported to show more than 60% absorption rate when orally administered to dogs. Clinical trials are underway ( PNAS , 1995, 92, 7001-7005; Endocrinology , 1996, 137, 5284-5289). The results of these studies suggest that substances that stimulate the pituitary gland to secrete growth hormone may be useful clinically as growth hormone replacements, while developing new growth hormone secretagogues is not easy. Shows.

As part of such research, researches on finding substances that promote growth hormone secretion using natural extracts that are harmless to the human body are being conducted. Examples include alcoholic extracts of Astragalus root and 7-hydroxy-4'-methoxy-isoflavone, formononetin and stigmas-4-en-6β-ol-3-one (stigmast-4-en-6β-ol-3-one) and the like have been confirmed by the present inventors to stimulate growth hormone secretion (Korean Patent Registration Nos. 257840 and 251519; Kim , JS and Kim, CS, Kor. J. Pharmacogn ., 1997, 28 (2), 75-79; Kim, JS et al., Kor. J. Pharmacogn. , 1996, 27 (4), 336-341) Growth hormone secretion stimulating composition (Korean Patent Application No. 1998-0053921), which contains one or more extracts selected from the group consisting of extracts of the ground, extracts of the casualties, lily extracts, and Giltyeong extracts, extracts of growth hormone secretion from natural herbal medicines Method and water-soluble fast extract (Korean Patent Application No. 1998-014589) and ascorrosapo of glycoalkaloids A study on the growth hormone secretagogue (Korean Patent Application No. 1998-014590) of nin H1 (asperosaponin H1) has been reported.

On the other hand, Samchil- Keun ( Panax notoginseng (Burk.) FH Chen) is a perennial herb of the elm family, which is smaller than ginseng, has 7 leaflets, and the roots are shaped like small North Koreans. The plant is three to seven branches attached to the leaves Samchil, the shape is similar to Chosun Ginseng, also called samchil ginseng. The roots contain 3-8% saponins, the main constituents of which are ginsenosides Rb1, Rg1, Re and notoginsenosides R1, R2, Fa, Fc, and a small amount of ginsenosides. There are R2, b2, d, e, c and there is no or very little R0. The composition of essential oil is less than ginseng and also contains oleanolic acid. Roots have hemostatic and cardiovascular effects, and animal studies have shown that they increase blood flow in the coronary arteries, reduce oxygen consumption in the myocardium, and reduce lipid and cholesterol levels in the blood. In addition, Samchil-Geun has excellent anti-inflammatory, analgesic, and hemostatic effects, which is effective for many inflammatory diseases including hepatitis, as well as for bleeding and internal bleeding caused by trauma and cuts.

Accordingly, the present inventors completed the present invention by revealing that while extracting the growth hormone secretion from natural herbal medicines, Samchil-Geun extract acts as a growth hormone secretagogue to increase the production of growth hormone.

The present invention is to provide a composition for promoting growth hormone secretion as an active ingredient Samchil muscle extract.

The present invention provides a composition for promoting growth hormone secretion as an active ingredient Samchil root extract.

Compositions of the present invention include pharmaceutical compositions and health food compositions useful for promoting growth hormone secretion.

Hereinafter, the present invention will be described in detail.

Samchil-geun extract of the present invention, the extract is extracted with water, alcohol or a mixed solvent of water and alcohol. The alcohol is preferably ethanol.

The extraction method may be a conventional extraction method such as cold needle, warm needle, heating using the solvent.

Specifically, the three-quarters dry powder in 70% ethanol aqueous solution and stirred at room temperature for 2 days, and then the solution is filtered through a filter paper. Repeat this process three times. The filtrate was concentrated under reduced pressure to remove ethanol, and then freeze-dried to remove moisture to obtain Samchil root extract.

Samchil-geun extract of the present invention acts on the pituitary cells to promote the secretion of growth hormone, and because it strongly increases the growth hormone in vitro ( in vitro ) as well as in vivo , microcertification, dwarfism, development of children It can be usefully used for the prevention and treatment of growth diseases such as sluggishness and growth slowdown.

The composition of the present invention may contain one or more active ingredients exhibiting the same or similar functions in addition to the three-stage muscle extract.

The three muscle root extract can be administered orally or parenterally during clinical administration and can be used in the form of a general pharmaceutical preparation. In other words, the three-stage muscle extract of the present invention may be administered in various oral and parenteral formulations during actual clinical administration, and when formulated, diluents such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants that are commonly used Or using excipients. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules, and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose and gelatin, etc. Are mixed to prepare. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups, and may include various excipients such as wetting agents, sweeteners, fragrances and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin and the like can be used.

Dosage units may contain, for example, one, two, three or four times the individual dosage, or they may contain 1/2, 1/3 or 1/4 times. The individual dosage preferably contains an amount in which the effective drug is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dose. The effective dose of Samchil root extract is 10 to 1,000 mg / kg, preferably 30 to 3,000 mg / kg, and may be administered 1-6 times a day.

As a result of the toxicity experiment by orally administering the extract of the present invention to rats, 50% lethal dose (LD ₅₀ ) by the oral administration toxicity test is determined to be a safe substance of at least 5g / kg or more.

The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers to promote growth hormone secretion.

The composition of the present invention can be added to health food for the purpose of promoting growth hormone secretion. When the three roots of the present invention is used as a food additive, the three roots of the extract may be added as it is, or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment). Generally, in the preparation of food or beverage, the three-quarters root extract of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less based on the raw material. However, in the case of long-term intake for health and hygiene or health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .

There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. The above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acid. Carbonating agents and the like used in beverages. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, preferred examples and experimental examples are presented to help understand the present invention. However, the following Examples and Experimental Examples are provided only to more easily understand the present invention, and the contents of the present invention are not limited by the Examples.

Example  : Preparation of Samchil-Geun Extract

50 g of dry samgeun root powder was added to 3 L of an aqueous 70% ethanol solution and stirred at room temperature for 2 days. After 2 days, the solution was filtered through filter paper, and this process was repeated three times. The filtrate was concentrated under reduced pressure to remove ethanol, and then freeze-dried to remove moisture to obtain Samchil root extract.

Experimental Example 1  : Growth Hormone Secretion Activity Test Using Samchil-Geun Extract (In vitro)

In order to determine the effect of the extract of Samchil-geun of the present invention on promoting growth hormone secretion, the following experiment was performed.

1-1. Pituitary Cell Culture

The pituitary gland was removed from Sprague-Dawley rats 4 to 5 weeks of age under aseptic manipulation, followed by collagenase (Gibco co., Grand Island, NY) and hyaluronidase (hyaluronidase, Sigma co). , St. Louis, Mo.) rat rat pituitary cells were isolated. Isolated pituitary cells were suspended in Dulbecco's Modified Eagle's medium containing 10% horse serum, 2.5% fetal bovine serum (FBS), and antibiotics, followed by Incubated at 37 ° C., 5% CO ₂ ).

1-2. Growth hormone secretion promoting activity experiment

The pituitary cells isolated in 1-1 were cultured and then suspended in the test solution. Samchiol-geun extract prepared in the above Example was added to the pituitary cells at a concentration of 1 mg / ㎖, rat growth hormone secretion factor (rat GRF, Bachem Co., Torrance, CA, which is a reference substance of growth hormone secretion) USA) was added to 300nM, 500nM, 1,000nM and then the test solution was added to a total volume of 1ml and incubated for 15 minutes at 37 ℃. After incubation, the supernatant was separated by centrifugation, and stored at -70 ° C to measure growth hormone.

Growth hormone measurement was performed using a rat growth hormone RIA kit (rat GH RIA kit, Amersham, Buckinghamshire, England).

The growth hormone contained in a constant amount of ¹²⁵ I-labeled growth hormone and the test substance stored in the above was tested by different reactions of the growth hormone-antibody complex (GH) by a competitive response to an anti-GH antibody. -Ab complex) was formed and precipitated by addition of a second antibody, and then the concentration was calculated using a standard curve by measuring the radioactivity of ¹²⁵ I from the precipitate.

The results are shown in Table 1.

Added concentration Growth hormone concentration (ng / ml) Control 0 3.063 Comparative group (rat growth hormone secretion factor) 300 nM 4.039 500 nM 5.238 1,000 nM 54.499 Samchil-Geun Extract 1 mg / ml 157.551

As shown in Table 1, the three-stage muscle extract of the present invention acts on the pituitary cells to promote the secretion of growth hormone, and the growth hormone secretion effect is superior to the rat growth hormone secretion factor used as a comparison group.

Experimental Example 2  : Rat growth hormone secretagogue activity test (In vivo)

Six-week-old SD rats were anesthetized at a concentration of 50 mg / kg of pentobarbital, and then the extract of Samchil-Geun prepared in Example 1 was dissolved in physiological saline at a concentration of 1 mg / kg and administered to the jugular vein of the rat.

Physiological saline was administered as a control.

After collecting blood from the tail jugular vein at a predetermined time interval, growth hormone secreted in the same manner as in Experimental Example 1 was measured using a RIA kit.

The results are shown in FIG.

As shown in Figure 1, the group administered the Samchil-Gil extract increased growth hormone secretion between 20-40 minutes after injection. That is, it was confirmed that the growth hormone concentration increased by about 5 times compared to the control group.

Experimental Example 3  : Acute Toxicity of Oral Administration in Rats

In order to determine the acute toxicity of Samchil-geun extract of the present invention, an acute toxicity test was conducted in the following manner.

Acute toxicity test was conducted using 6-week-old specific pathogen-free (SPF) SD rats. Two animals per experimental group were suspended orally administered once at a dose of 1 g / kg / ml by suspension of the three-stage muscle extract of the present invention in 0.5% methylcellulose solution, respectively. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and hematological examinations were performed.

As a result, no significant clinical symptoms or dead animals were noted in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings.

Therefore, all three of the extracts of the present invention showed no toxicity change to rats up to 5 g / kg, and the minimum lethal dose (LD ₅₀ ) of oral administration was determined to be a safe substance of at least 5 g / kg or more.

Examples of preparations for the compositions of the present invention are illustrated below.

Formulation Example 1  : Preparation of Pharmaceutical Formulations

1. Preparation of Injection Solution

Injection solution containing 10 mg of the active ingredient was prepared by the following method.

100 g of 1 g of Samchil root extract, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water. The solution was bottled and sterilized by heating at 20 ° C. for 30 minutes.

The components of the injection solution are as follows.

1 g extract

0.6 g sodium chloride

0.1 g of ascorbic acid

Distilled Water Determination

2. Preparation of Syrup

Syrup containing 3% root extract of the present invention as an active ingredient (% by weight / volume) was prepared by the following method.

Samchil root extract, saccharin, and sugar were dissolved in 80 g of warm water. After the solution was cooled, a solution consisting of glycerin, spices, ethanol, sorbic acid and distilled water was prepared and mixed therein. Water was added to this mixture to 100 ml.

The components of the syrup are as follows.

Ginseng extract 2 g

Saccharin 0.8 g

25.4 g per

Glycerin 8.0 g

0.04 g of spices

Ethanol 4.0 g

0.4 g of sorbic acid

Distilled Water Determination

3. Preparation of Tablets

A tablet containing 15 mg of the active ingredient was prepared by the following method.

It was mixed with 250 g of Samchil root extract, 175.9 g of lactose, 180 g of potato starch, and 32 g of colloidal silicic acid. 10% gelatin solution was added to the mixture, which was then ground and passed through a 14 mesh sieve. It was dried and a mixture obtained by adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate was prepared as a tablet.

The components of the tablet are as follows.

250 g of Samchil root extract

Lactose 175.9 g

180 g potato starch

32 g of colloidal silicic acid

10% gelatin solution

Potato Starch 160 g

50 g of talc

5 g of magnesium stearate

Formulation Example 2  : Manufacture of food

Food containing the three-stage root extract of the present invention was prepared as follows.

1. Preparation of Cooking Seasonings

Samchil-geun extract of the present invention 20 to 95% by weight to prepare a cooking seasoning for health promotion.

2. Preparation of Tomato Ketchup and Sauce

Health-promoting tomato ketchup or sauce was prepared by adding 0.2 to 1.0% by weight of Samchil-Geun extract of the present invention to tomato ketchup or sauce.

3. Manufacturing of Flour Foods

0.5 to 5.0% by weight of the three-stage root extract of the present invention was added to wheat flour, and bread, cake, cookies, crackers, and noodles were prepared using the mixture to prepare foods for promoting health.

4. Preparation of soups and gravy

Samchil-geun extract of the present invention was added to 0.1 ~ 5.0% by weight to soup and gravy to prepare a health-promoting meat products, soup of noodles and gravy.

5. Preparation of Ground Beef

10% by weight of the extract of Samchil-geun of the present invention was added to ground beef to prepare ground beef.

6. Manufacture of Dairy Products

5 to 10% by weight of the extract of Samchil-geun of the present invention was added to milk, and the milk was used to prepare various dairy products such as butter and ice cream.

7. Manufacture of wire

Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh using a grinder.

Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.

The extract of the present invention was concentrated under reduced pressure and concentrated in a vacuum concentrator, and the dried product obtained by drying with a sprayer and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.

It was prepared by combining the dry powder of the grains, seeds and samchil root extract prepared above in the following ratio.

Cereals (30% by weight brown rice, 15% by weight radish, 20% by weight barley),

Seeds (7% by weight perilla, 8% by weight black beans, 7% by weight black sesame),

Dry powder of samchil-geun extract (3% by weight),

Ganoderma lucidum (0.5% by weight),

Foxglove (0.5 wt%)

Formulation Example 3  : Preparation of Beverages

1. Preparation of Carbonated Drinks

5-10% of sugar, 0.05-0.3% citric acid, 0.005-0.02% caramel, 0.1-1% of vitamin C are mixed, and 79-94% purified water is mixed to make syrup, and the syrup is 85-98 Sterilizing at 20 ℃ for 180 seconds to mix with a cooling water 1: 1: ratio of carbon dioxide gas was injected 0.5 ~ 0.82% to prepare a carbonated beverage containing the samchil root extract of the present invention.

2. Manufacture of health drinks

Instant sterilization by homogeneously mixing subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%) , Packed in a small packaging container such as plastic bottles to prepare a healthy beverage.

3. Preparation of Vegetable Juice

5 g of the three-stage root extract of the present invention was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice for health promotion.

4. Preparation of Fruit Juice

1 g of the extract of Samchil-geun of the present invention was added to 1,000 ml of apple or grape juice to prepare fruit juice for health promotion.

Samchil-geun extract of the present invention acts on the pituitary cells to promote the secretion of growth hormone, and because it strongly increases the growth hormone in vitro ( in vitro ) as well as in vivo , microcertification, dwarfism, development of children It can be usefully used for the prevention and treatment of growth diseases such as sluggishness and growth slowdown.

Claims (2)

Pharmacy for the treatment or prevention of growth diseases caused by growth hormone deficiency selected from the group consisting of microcertification, dwarfism, undergrowth and hypoplasia of children by promoting the secretion of growth hormone, which contains the extract of Samchil-Geun as an active ingredient Composition. A health food composition for growth diseases caused by growth hormone deficiency selected from the group consisting of subauthentication, dwarfism, underdeveloped children and reduced growth by promoting the secretion of growth hormone containing the samchil root extract as an active ingredient.

Images